• Login | Register

Conference Details - Overview

Current Trends in the Treatment of Haematologic Malignancies

Swissôtel The Bosphorus, Istanbul
Istanbul, Turkey
Jan 17, 2009

Conference Overview

Conference Description & Purpose

Not CME-Certified

Current Trends in the Treatment of Haematologic Malignancies is a symposium designed to update practicing medical oncologists, haematologists, and nurses on data on the treatment and management of leukaemia, lymphoma, and myeloma presented at major haematology conferences in 2008. Novel agents for the treatment of haematologic malignancies and recent developments in supportive therapy will also be discussed. These advances will be addressed through presentations by key thought leaders, interactive case discussions, and question-and-answer opportunities. The overall objective of the symposium is to provide updates on treatment options that can be integrated into the treatment of patients with various haematologic malignancies as well as enhance awareness of novel agents that are in development in order to increase the number of patients enrolled in clinical trials.

Target Audience

This educational programme is directed toward medical oncologists and haematologists interested in the treatment of haematologic malignancies. Nurses, fellows, pharmacists, and others interested in the treatment of cancer are also invited to attend.

Learning Objectives

At the conclusion of this symposium, you should be able to:

• Evaluate current treatment options for the management of aggressive non-Hodgkin lymphoma, including the use of monoclonal antibodies to improve survival
• Compare treatment options for newly diagnosed and relapsed/refractory multiple myeloma, including regimens containing immunomodulatory agents and proteasome inhibitors
• Describe recent advances in the management of mantle cell and T-cell lymphomas with monoclonal antibodies, histone deacetylase inhibitors, and proteasome inhibitors
• Assess the role of monoclonal antibodies in the treatment of low-grade non-Hodgkin lymphoma, including their potential in improving clinical outcomes
• Evaluate the potential of emerging novel agents to improve response in patients with relapsed/refractory non-Hodgkin lymphoma
• Discuss next-generation tyrosine kinase inhibitors and other novel agents in the management of patients with chronic myeloid leukaemia who develop resistance to initial therapy
• Describe emerging agents in the treatment of multiple myeloma, including novel proteasome inhibitors and novel formulations of anthracyclines
• Analyze the safety and efficacy of immunomodulatory and hypomethylating agents, growth factors, and novel agents in the optimal management of myelodysplastic syndromes
• Integrate novel treatment regimens into the management of chronic lymphocytic leukemia, including monoclonal antibodies in combination with growth factors, purine analogues, and other targeted agents
• Compare novel agents in the optimal management of acute leukaemias, including farnesyltransferase inhibitors, purine nucleoside analogues, and kinase inhibitors
• Compare the different emerging treatment options for patients with idiopathic thrombocytopenic purpura
• Implement advances in supportive care for patients with haematologic malignancies, including the prevention of tumour lysis syndrome; mobilisation of stem cells for transplantation; and management of iron overload, anaemia, and neutropenia